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HUMAN UMBILICAL CORD BLOOD (HUCB) DERIVED STEM CELLS AND
THEIR POTENTIAL IN TREATING INHERITED SKIN DISEASES AND PRO-
MOTION OF WOUND HEALING
Liao, Y., Yang, A., Gold, J., Street, L., Baxi, L.V., Ayello, J., Vandeven, C.,
Cristiano, A., Cairo, M.S. Columbia University, New York, NY
Recessive Dystrophic Epidermolysis bullosa (RDEB) is a severe
inherited skin-blistering disease caused by mutations in the
Col7A1 gene. COL7A1 is synthesized by keratinocytes and fibro-
blasts and is a major component of anchoring fibrils that extend
from basement membrane to papillary dermis. A recent animal study
suggested that the hematopoietic enriched cells ameliorated the blis-
tering phenotype in the RDEB mice. However, only limited donor
epithelial engraftment and COL7A1 protein were observed and
the possibility of rare stem cells co-purifying with enriched cells can-
not be excluded. As multiple populations of primitive stem cells with
multi-lineage differentiation potential have been identified from
HUCB, including unrestricted somatic stem cells (USSCs), they
may offer potential for the treatment of RDEB.
Goal:To isolate USSCs fromHUCB and determine the potential in
treating RDEB and promoting wound healing.
Methods: USSCs were initiated from HUCB in 30% FBS and
1027M dexamethasone. Q-RT-PCR was utilized to assess gene ex-
pression of Nanog, Oct4, Sox2 and Col7A1. DNA methylation at
the enhancer and promoter of both Oct4 and Nanog genes was
analyzed by bisulfate sequencing. The expression of CCR2 was ana-
lyzed by immunocytochemistry.
Results: HUCB-USSCs are lineage negative and share overlapping
but distinct surface markers withMSCs. They express a low but con-
sistent level of Nanog, Oct4 and Sox2. Significantly, the Nanog and
Oct4 expression inUSSCs is about 20- and 400- fold higher than that
in humanfibroblasts.Their levelwas further increased10 fold follow-
ing the treatmentwithDNAmethylation inhibitor, 5-azacytidine. An
average of 65% and 47% of the CpGs were unmethylated in the en-
hancer and promoter of theNanog gene respectively, while 56% and
80% were unmethylated at those of the Oct4 gene. We also showed
that USSCs express Col7A1, at a level comparable to human kerati-
nocytes, suggesting that USSCs, once engraft in the skin, could res-
cue the defective anchoring fiber formation by secreting COL7A1.
In addition,we demonstrated thatUSSCs express theCCR2, a recep-
tor for several chemoattractant proteins, such as MCP-1, that have
been shown to be highly expressed in the dermal wounds, implying
a migratory ability of USSCs under wound conditions. We are now
investigating the role of USSCs in promoting wound healing in
immunodeficient mice with excisional wounds and comparing the
effects of routes of injection on their long-term engraftment.322
ASSESSMENT OF THE BONE MARROW COMPARTMENT VOLUME AND
EFFECT OF CHEMORADIOTHERAPY USING 18F-FLUOROTHYMIDINE
Holter, J.L.1, Slart, R.H.J.A.2, Challis, M.1, Selby, G.B.1, Lerner, M.1,
Epstein, R.B.1 1University of Oklahoma, Oklahoma City, OK; 2Univer-
sity of Groningen and University Medical Center of Groningen, Gronin-
gen, Netherlands
Evaluation of the bone marrow compartment currently consists of
a combination of bone marrow histology obtained by bone marrow
biopsy, assessment of bone marrow with molecular analysis, and kar-
otype genetics. Despite the recent excitement of additional modali-
ties such and fluorodeoxyglucose (FDG) PET imaging and MRI,
neither have proven to be accurate nor are clinically reproducible.
We describe the use of Fluorothymidine-PET imaging to quantitate
marrow volume in seven patients with normal marrow diagnosed
with brain tumors (n 5 4) and lymphoma with negative marrow (n
5 3). Marrow volume was calculated by three-dimensional assess-
ment of SUV uptake in marrow sites at pelvis, cervical, thoracic,
and lumbar vertebrae, sternum, bilateral humeri and femurs. Average
marrow volume for seven patients noted to be 2308 ml. Marrow dis-
tribution shows the following: pelvis 65%, cervical 1%, thoracic
11%, lumbar 10%, humeri 4%, femurs 4%, sternal 5%. We further
describe the reproducibility of imaging using this agent post chemo-
therapy and post radiotherapy in patients with testicular (n5 9) andlaryngeal carcinoma (n 5 10). Radiation therapy(RT) to cervical
spine was consistent with clinical observation with a decline in mar-
row SUV from 3.0 61.34 before RT to 1.946 0.60 (P0.013) after
RT. Chemotherapy resulted in no significant change in SUV when
tested 6 months after last dose of chemotherapy with a mean SUVmax
of 4.9961.15 pre-chemotherapy andmeanSUVmaxof 5.2861.0 post-
chemotherapy (P0.21). We suggest that FLT-PET imaging may be
a useful tool for the assessment of the marrow compartment and may
be useful for assessment of marrow injury following radiotherapy.323
WNT/b-CATENIN SIGNALING COOPERATES WITH PTEN/PI3K/AKT SIG-
NALING IN VIVO AND EX VIVO TO PROMOTE HEMATOPOIETIC STEM
CELL SELF-RENEWAL AND EXPANSION
Perry, J.M.1, He, X.C.1, Grindley, J.C.1, Abhyankar, S.2, Weiner, C.3,
Li, L.1,4 1Stowers Institute forMedical Research, Kansas City, MO; 2Uni-
versity of Kansas Medical Center, Kansas City, KS; 3University of Kansas
Medical Center, Kansas City, KS; 4University of Kansas Medical Center,
Kansas City, KS
Although self-renewal is the central property of stem cells, the un-
derlying mechanism remains inadequately defined. Separately, the
PTEN/PI3K/Akt and Wnt/b-catenin signaling pathways have
been implicated in regulating hematopoietic stem cells (HSCs),
but neither pathway is sufficient for self-renewal. Using a HSC
and progenitor (HSPC)-specific conditional mutant mouse model,
we studied Pten deletion combined with b-catenin activation. In con-
trast to single mutants, double mutant mice exhibit a novel pheno-
type including expansion of phenotypic HSCs without extensive
differentiation. Together, the PTEN/Akt and Wnt/b-catenin path-
ways interact to drive HSC expansion by inducing proliferation
while simultaneously inhibiting apoptosis and blocking differentia-
tion—demonstrating the necessity of complementary cooperation
between the two pathways in promoting self-renewal. Mechanisti-
cally, this is accomplished by upregulation of the HSC self-renewal
related gene HoxB4 and Inhibitor of differentiation 2 (Id2) combined
with downregulation of the apoptosis inducer s100A8/A9 in double
mutants. Informed by this genetic model, we developed an ex vivo
HSC expansion protocol. In serial transplantation experiments, si-
multaneous activation of both PTEN/Akt and Wnt/b-catenin path-
ways achieves long-term engraftment equivalent to a one-hundred
fold greater dosage of uncultured HSCs—demonstrating unprece-
dented expansion of long-term repopulating HSCs. This expansion
is achieved using serum-free media with low doses of cytokines but
without using feeder-cell layers or permanent genetic manipulation,
making our protocol ideal for potential translation into the clinic.324
LOWER VIABLE CD34 RECOVERY IN CRYOPRESERVED ALLOGENEIC
PBSC COMPARED TO AUTOLOGOUS PBSC
Antonenas, V.1, Garvin, F.1, Gottlieb, D.1, Trickett, A.2 1Westmead Hos-
pital, Sydney, NSW, Australia; 2ACI, Sydney, NSW, Australia
Allogeneic peripheral blood stem cells (PBSC) are cryopreserved
less often than autologous harvests. The use of cryopreserved alloge-
neic HPC is becoming increasingly common for storage of excess
HPC or T cells for donor lymphocyte infusions, in addition to cir-
cumventing issues of donor availability particularly in light of recent
worldwide events (Sept 11, swine flu and flight disruptions due to
volcanic ash).
During 2006 to 2009, our cell processing laboratory cryopre-
served 30 allogeneic and 350 autologous PBSC. It was noted that
the post-thaw viable CD34+ recovery was lower in allogeneic
PBSC products (median63%, range 16-92) than autologous (72%,
13-151; p\ 0.0004). Hence this study aimed to determine factors
that influence post-thaw CD34 recovery.
We analysed data from all cryopreserved allogeneic and autolo-
gous PBSC, with the aim of determining the effect of cryopreserved
nucleated cell concentration (NCC), neutrophil content, and time
from collection to cryopreservation.
Univariate analysis demonstratedweak inverse correlationswere be-
tween viable CD34 recovery and NCC (Spearman r 5 -0.20, p\
0.0001), collection to freeze time interval (r 5 -0.10, p 5 0.048),S271
S272 Poster Session Ineutrophil content (r5 -0.20, p\0.0001).Multiple regression analysis
demonstrated that collection to freeze interval (p5 0.006), neutrophil
content (p\ 0.0001) and allogeneic donors (p\ 0.001) significantly
affected viable CD34 recovery, but NCC did not (p5 0.14).
Of the 35 cryopreserved allogeneic products, 11 have been infused
with no significant difference in terms of engraftment of neutrophils
(median 18; range 11-31) and platelets (median 27; range 14-58),
when compared to infusion of 179 fresh allogeneic products (neutro-
phils: median 17, range 4-55, p 5 0.9; platelets: median 19, range1-
101, p 5 0.2).
This data indicates that the lower post-thawviableCD34 recovery in
PBSCmaybedue to intrinsicpropertiesof allogeneicdonor inaddition
to the neutrophil content and prolonged storage periods prior to cryo-
preservation. Post thawanalysis of viableCD34+ content is recommen-
ded to ensure sufficient viable CD34+ to facilitate engraftment.
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CREATION OF A SEGMENT-BASED ALDEHYDE DEHYDROGENASE ASSAY
AS A BIOMARKER FOR UMBILICAL CORD BLOOD POTENCY
Shoulars, K.1, Gentry, T.2, Page, K.1, Balber, A.2, Kurtzberg, J.1 1Duke
University Medical Center, Durham, NC; 2Aldagen Inc, Durham, NC
Banked, unrelated umbilical cord blood units (CBU) provide an op-
tion for transplantation for patients lacking matched donors. Current
methods for selecting a suitableCBU for transplantation include exam-
ining the human leukocyte antigen (HLA) matching, total nucleated
cell (TNC) count, and, in some situations, viable CD34 counts on
the unit prior to cryopreservation. However, 20% of patients experi-
ence primary graft failure following UCB transplantation (UCBT),
suggesting a better assay to assess potency on a thawed CBU prior to
the release from the cord blood bank is needed. Preliminary clinical
studies demonstrated that neutrophil and platelet engraftment as well
asoverall survival canbepredictedwithpost-thawcolony formingunits
(CFU). The usefulness of post-thawCFU as a potency assay is limited
both by time (14 days) and variability. However, CFUs in fresh cord
blood are highly correlated with the number of hematopoietic progen-
itor cells expressing high levels of the enzyme aldehyde dehydrogenase
(ALDHbr cells). Retrospective studies of transplanted CBUs indicated
that engraftment success was accurately predicted by the number of
ALDHbr cells infused per kilogram. Therefore, we developed an
ALDHbr assay for segments attached to CBUs to measure potency
for UCBT on segments used for HLA confirmatory typing (CT).
Wemeasured CFUs and flow cytometric analysis on 334 segments re-
quested for CT. Each segment was thawed and blood was spotted on
a FTA card for CT. The remaining blood was washed with 5% dex-
tran/albumin to remove the DMSO. Following removal of 100,000
white blood cells for CFU, the content of ALDHbr [Aldecount],
CD34+, CD45+, glycophorin A+ and viable (7-AAD+) cells was mea-
sured by flow. Comparisons of the data from the CT segments show
thatALDHbr correlateswellwithCFUs (R25 0.809), at a ratio approx-
imately 4 ALDHbr cells per 1 CFU. In contrast, CFU and ALDHbr
counts do not correlate well with viableCD45+ or viable CD34+ count.
Of the 334 units assayed, 82 have been administered to patients.
Several graft parameters of potential use in measuring potency of
a CBU can be measured prospectively on a segment at the time of
CT and can provide information for unit selection. Using unit values
calculated from the CT segment, we will compare clinical outcomes
to the graft parameters in order to determine which provide predic-
tive information concerning neutrophil and platelet engraftment and
overall survival after UCBT.SUPPORTIVE CARE
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COLLECTION OF G-CSF-MOBILIZED GRANULOCYTES FROM RELATED
DONORS TO SUPPORT HEMATOPOIETIC STEM CELL TRANSPLANT RE-
CIPIENTS AT HIGH RISK OF INFECTION IS SAFE AND FEASIBLE
Tewari, P.1, Allison, J.1, Waters-Pick, B.2, Cash, J.V.1, Kurtzberg, J.1,
Prasad, V.K.1 1Duke University Medical Center, Durham, NC; 2Duke
University Medical Center, Durham, NC
Background: Granulocyte transfusions may be useful for patients
undergoing hematopoietic stem cell transplantation (HSCT) at
high risk for the development of life-threatening infections during
the neutropenic period. However, their usefulness depends on feasi-bility and safety of repeated collections of GCSFmobilized granulo-
cytes from related donors.
Methods: A total of 1,536 leucophereses to collect granulocytes
from 148 GCSF-mobilized related donors were performed between
1999 and 2009 at Duke to treat 139 HSCT recipients. Donors were
screened by a rigourous health history questionnaire and by blood
tests for a number of infectious diseases. Central venous line
(CVL) placement was performed under sedation or anesthesia. Sub-
cutaneous G-CSF (10mcg/kg) was given the night before pheresis,
twice weekly. Each collection was divided into 3 aliquots and infused
daily to provide dosing for 6 days per week. Donors received oral
iron, vitaminK, and calcium supplements. They were carefully mon-
itored with regular clinical and laboratory tests for any adverse ef-
fects. All products were regularly assayed for total nucleated cell
counts (TNC), viability and sterility.
Results: Of 148 donors, 74 were male and 62 CMV seropositive.
Their median age was 36.8 years (range: 17-58) and median weight
was 79.3 kg (50.9 - 183.5). Donors were fathers (n 5 72), mothers
(n 5 57), siblings (n 5 8), or other relatives (n 5 11). Past medical
history was negative in all but 13 donors (asthma, n 5 5; hyperten-
sion, n 5 3; diabetes, n 5 1; others, n 5 4). Donors underwent
a median of 8 phereses (range, 1-71) over a median of 25 days (range,
1-266). Complications included pruritis (n 5 8), fever (n 5 3), bac-
teremia (n5 15), CVL tract infection (n5 1), exit site related minor
bleeding (n5 3), local discharge (n5 7), and erythema (n5 8). Five
required 2 or more CVLs. Laboratory abnormalities included LFT
elevation (n5 1), PT. 16 sec (n5 2), and fibrinogen\100 mg/dL
(n 5 1). Between the first and the last pheresis, the median drop in
Hemoglobin was 2.5 gm/dL (range, 0-6.8) and the drop in serum al-
bumin was 0.6 gm/dL (range, 2-2.2). Ten of 1536 granulocyte prod-
ucts were contaminated with bacteria. Pheresis was stopped for all
fevers and positive line cultures.
Conclusions:When performed at an experienced center using well
defined guidelines and good supportive care, granulocyte collection
from family donors following GCSF stimulation is safe and feasible.327
ERYTHROPOIETIN-ASSISTED PHLEBOTOMY IN STEM CELL TRANSPLANT
PATIENTS WITH IRON OVERLOAD
Schwalier, E., Laws, A., Osswald, M.B. San Antonio Military Medical
Center
Stem cell transplantation often necessitates repeated transfusions
raising the risk of secondary hemochromatosis. Erythropoietin-as-
sisted phlebotomy (EAP) is a potential treatment to alleviate iron
overload in these patients.
Methods: We carried out a retrospective review of 372 stem cell
transplants at our hospital from 2000 to 2008.We evaluated themax-
imum ferritin level for each patient and used a level of 1,000 ug/mL
to identify patients at increased risk for complications of iron over-
load. 65 patients had ferritin levels\1,000ug/mL and served as con-
trols. Groups were further subdivided into those who received
therapeutic EAP and those who did not. Records were also reviewed
for transplant related infections.
Results: Among the 56 patients with ferritin levels over 1,000ug/
mL, the average ferritin level was 2,965ug/mL. These patients re-
ceived an average of 26.6 units of transfused PRBCs during their
transplant course. Ten of these patients underwent EAP of 500cc
of blood approximately every two weeks to decrease their ferritin
level. The non-phlebotomized group had an increased rate of infec-
tions and trended toward a higher mortality. The non-phlebotomy,
hyperferritinemia group had the highest rates of infection within our
three groups at both three and six months (p\0.004 and p\0.008)
but not at 1 year (p\ 0.086). There was no significant difference in
infection rates in the EAP group and the controls at either 3 or 6
months. (p\ 0.17, p\ 0.107) Mortality differences between the
two main groups (ferritin . 1,000ng/ml and ferritin\ 1,000 ng/
ml) were significant at both six months and one year (p\ 0.0004
and p\ 0.005 respectively). There was also a significant difference
between the hyperferritinemia group who did not receive EAP and
controls at both six months and one year (p \ 0.00002 and p \
0.0004 respectively). Two-tailed Fishers exact test showed that the
mortality rate between the two subsets in the hyperferritinemia
group was significant at six months (p 5 0.009 two sided; p 5
